These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3234596)

  • 1. Modified release tizanidine in the treatment of spasticity.
    Chantraine A; Van Ouwenaller C
    J Int Med Res; 1988; 16(6):459-65. PubMed ID: 3234596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified release tizanidine: a review.
    Hutchinson DR
    J Int Med Res; 1989; 17(6):565-73. PubMed ID: 2697626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
    Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke.
    Gelber DA; Good DC; Dromerick A; Sergay S; Richardson M
    Stroke; 2001 Aug; 32(8):1841-6. PubMed ID: 11486114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia.
    Bes A; Eyssette M; Pierrot-Deseilligny E; Rohmer F; Warter JM
    Curr Med Res Opin; 1988; 10(10):709-18. PubMed ID: 3286129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease.
    Ogawa N; Asanuma M; Hirata H; Ota Z; Yamawaki Y; Yamamoto M
    J Int Med Res; 1992 Feb; 20(1):78-86. PubMed ID: 1568522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
    Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
    Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
    Medici M; Pebet M; Ciblis D
    Curr Med Res Opin; 1989; 11(6):398-407. PubMed ID: 2651016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
    Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
    Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
    Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
    Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective assessment of tizanidine for spasticity due to acquired brain injury.
    Meythaler JM; Guin-Renfroe S; Johnson A; Brunner RM
    Arch Phys Med Rehabil; 2001 Sep; 82(9):1155-63. PubMed ID: 11552184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
    Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
    Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
    Henney HR; Shah J
    Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summary of combined clinical analysis of controlled clinical trials with tizanidine.
    Wallace JD
    Neurology; 1994 Nov; 44(11 Suppl 9):S60-8; discussion S68-9. PubMed ID: 7970013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tizanidine for spasticity.
    Med Lett Drugs Ther; 1997 Jul; 39(1004):62-3. PubMed ID: 9217694
    [No Abstract]   [Full Text] [Related]  

  • 19. [The use of sirdalud MR in patients with multiple sclerosis].
    Batysheva TT; Popova NF; Petrov SV; Kamchatnov PR; Zaĭtsev KA; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):57-60. PubMed ID: 21322181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
    Vakhapova V; Auriel E; Karni A
    Clin Neuropharmacol; 2010 May; 33(3):151-4. PubMed ID: 20502134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.